Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HDL Clear all

Conditions: HDL
Interventions: CardioLux™HDL, Placebo; Dietary Supplement
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Familial Hypercholesterolemia
Interventions: 2-Hydroxybenzylamine, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiovascular Disease
Interventions: Niacin Extended Release; Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Physicians' Practice Patterns, Coronary Heart Disease
Interventions: education and reminder; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 11,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hyperlipidemia
Interventions: Uncle Sam Cereal; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
Interventions: Pioglitazone, Life style diet group, Placebo; Drug · Behavioral · Other
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperlipidemias, Cardiovascular Diseases
Interventions: Dried blood spot testing and phlebotomy; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cholesterol, HDL
Interventions: Vinegar, Placebo; Dietary Supplement · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Fasting
Interventions: Fasting; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 20 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Davis, California

Conditions: Dyslipidemia
Interventions: LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 38
States / cities: Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more

Conditions: Chronic Kidney Disease
Interventions: Niacin, Active Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Combined Hyperlipidemia
Interventions: Pravafen, Pravastatin, Fenofibrate; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 57
States / cities: Phoenix, Arizona • Sierra Vista, Arizona • Long Beach, California + 46 more

Conditions: Lipid Metabolism
Interventions: stable isotope of cholesterol; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Green tea, 70% dark chocolate; Dietary Supplement
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diet Modification, Cardiology
Interventions: whole food, plant based diet; Behavioral
Lead sponsor: Lancaster General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Stable Atherothrombotic Disease
Interventions: CSL112 (reconstituted high density lipoprotein), Placebo; Biological
Lead sponsor: CSL Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Chula Vista, California • Jacksonville, Florida • Miami, Florida + 8 more

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Syndrome X
Interventions: LY518674; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections, Dyslipidemia, Endothelial Dysfunction
Interventions: extended release niacin; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Metabolic Syndrome
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 30 Years to 79 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Cardiovascular Diseases
Interventions: Low polyphenol concentration extra virgin olive oil (EVOO), High polyphenol concentration extra virgin olive oil (EVOO); Dietary Supplement
Lead sponsor: Ralph Hamill; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Brunswick, Maine • Rockport, Maine • Scarborough, Maine

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Lipid Metabolism Disorders
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dyslipidemia
Interventions: CP-778,875; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 31
States / cities: Anniston, Alabama • Huntsville, Alabama • Greenbrae, California + 26 more

Search by objective public record fields.

Oral Nutritional Supplement Effect on HDL Function

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

Effects of Niacin Therapy on Lipoprotein Composition and Function

From Research to Practice - Lipid Management for Low HDL-Cholesterol

A Controlled Trial of High Dietary Fiber Intake on Serum Lipids

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

Dried Blood Spot- Statin Pilot Study

Prospective Randomized Clinical Trial Evaluating the Impact of Vinegar on High Density Lipoprotein

Effects of Prolonged Fasting on Microbiome and HDL

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Niacin and Endothelial Function in Early CKD

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Dose of Labeled Cholesterol for Kinetics: A Pilot Study

Flavonoid Effect on Activation and Stimulation of Thrombocytes, hsCRP and Lipid Profile

A Whole Food Plant Diet and Its Lipidemic Effects on Primary Prevention in a Free-range Population

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

Melatonin and the Metabolic Syndrome

A Multicenter Pilot Study to Evaluate the Effect of EVOO on Lipid Parameters

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.